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the French Sickness Fund. METHODS: Medical consumption
was based on clinical trial data. Cost data (medical fees, hospi-
talization, surgery) were extracted from the National Health
Insurance website (www.ameli.fr) and from PMSI database.
Cost-efﬁcacy ratios were calculated to compare therapies when
signiﬁcant differences were demonstrated on study outcomes.
RESULTS: Costs per clinical progression prevented were respec-
tively €7404 for ﬁnasteride, €7314 for doxazosin, and €8206 
for the combination of both as compared with placebo. Cost-
efﬁcacy ratio (additional drug costs per invasive therapy avoided)
was €16,153 for ﬁnasteride versus placebo, and €3153 versus
doxazosin. It was €16,400 for combination therapy versus dox-
azosin, and €28,779 versus placebo. CONCLUSION: Cost-
efﬁcacy ratios of ﬁnasteride and doxazosin for the prevention of
clinical progression were in the same range. The cost-efﬁcacy
ratio of the combination was slightly higher, but with a further
signiﬁcant clinical beneﬁt. Only ﬁnasteride alone or in combina-
tion with doxazosine reduced the risk of invasive therapy. Its
cost-efﬁcacy ratio for preventing invasive therapy remains in an
acceptable range in the French setting.
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OBJECTIVES: To estimate the direct annual costs (from May
2004 to May 2005) associated with Lower Urinary Tract Symp-
toms (LUTS) in Italian women from the NHS perspective. To
assess, at the same time, costs borne by subgroup of women with
Urinary Incontinence (UI). METHODS: This evaluation was
carried out as a part of the FLOW project: a 2-year observational
study aimed at evaluating the prevalence, incidence and remis-
sion rates of LUTS in a large sample of women followed at 39
Italian Urology Clinics. NHS costs, such as specialist visits, hos-
pitalizations, therapy and laboratory tests were collected retro-
spectively. The Dowell-Bryant Incontinence Cost Index (DBICI)
was used to investigate personal UI costs, such as: disposable
pads, re-usable incontinence products, laundry and health pro-
fessional expenditure, surgery/diagnostic investigation and med-
ication. RESULTS: A sample of 279 women were re-evaluated
after two years follow-up. The estimated total annual cost to the
Italian NHS for curing female with LUTS ranged between
€70,488,843 and €1,325,850,296. The average annual NHS
costs per patient in our sample were €232.90, of which the major
components were: rehabilitative therapy (€83.24), surgical
therapy (€64.54) and instrumental tests (€47.39). As for women
with UI, surgery interventions accounted for 35% of the total
NHS costs Vs 27% for whole study sample with LUTS. Regard-
ing women with UI, the average annual personal cost estimated
by DBICI was 215.21€ of which disposable pads and medica-
tions accounted respectively for 50% and 33%. CONCLUSION:
After 2-yr follow-up the higher costs for the NHS seem to be
associated to rehabilitative therapy and surgical procedures.
Some differences were detected among the NHS resources used
by the subgroup of women with UI. Costs borne by women with
UI were quite high and the most important estimated component
were the use of disposable products.
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OBJECTIVES: This study’s objective was to estimate the burden
of illness (BOI) of overactive bladder (OAB) and urinary urge
incontinence (UUI) in the over 40 population using recent ﬁnd-
ings from a prevalence survey (EPIC) and recent published liter-
ature. METHODS: New prevalence data was incorporated into
a previously published BOI model. A literature search obtained
data pertaining to consequence probabilities for OAB, UUI and
related co-morbidities. The model was then used to produce esti-
mates of the total burden of OAB in 6 countries. RESULTS: It
is estimated, for these 6 countries, that that over 20 million
people have OAB symptoms of which 2 million have UUI. 
The annual total direct cost of OAB was calculated to be 12
billion euros (2005 prices). 80% of this cost is associated with
UUI. The total costs per country are: €257,402,489 Canada,
€5,301,967,560 Germany, €4,536,571,901 Italy, €550,697,531
Spain, €327,640,146 Sweden and €1,026,091,457 UK. The cost
of OAB management (medical visits, diagnostic testing, inconti-
nence pads and drugs) and co-morbidities (UTIs, skin conditions,
falls/fractures, depression and increased likelihood of nursing
home admission) ranged from €2600 in Spain to €35,000 in Italy
per person. The largest cost driver was the increased likelihood
of nursing home admission followed by the cost of incontinence
pads. CONCLUSIONS: These estimates of the total direct cost
burden of OAB are higher than previous published estimates.
This is due to current prevalence rates and probabilities of devel-
oping consequences of uncontrolled OAB. The OAB symptom
UUI is associated with the most co-morbidity costs. These 
COI results may under-estimate the true costs, as OAB also
affects people under 40 years old. Indirect and intangible costs
have also been excluded. Cost-effective treatments for OAB and
UUI in particular have the potential to signiﬁcantly improve the
allocation of health care resources in a growing proportion of
the population.
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OBJECTIVES: End-stage renal failure patients are normally
anaemic due to failure of renal to produce endogenous erythro-
poietin (EPO). Erythropoietin is used to treat anaemia in these
patients but the drug is expensive. The objectives of this study
were to determine the life expectancy, the improvement in quality
of life associated with haemoglobin, the utility of the dialysis
patients, and the cost utility as cost per quality-adjusted life year
(QALY) saved. METHODS: The perspective was for the health
provider and the treatments compared were haemodialysis and
CAPD. The National Renal Registry database for the period of
1997–2004 formed the basis of patient selection. There were 406
haemodialysis and 333 continuous ambulatory peritoneal dialy-
sis (CAPD) patients to evaluate the utility of quality of life. The
health-related quality of life questionnaires and the time trade-
off were used to acquire the quality of life index and the utility.
A388 Abstracts
The costs were valued in terms of year 2004 Ringgit Malaysia
(RM). Sensitivity analyses were performed. RESULTS: Erythro-
poietin therapy improved the mean haemoglobin level of
anaemic haemodialysis patients by 9.39% and CAPD patients
by 8.48% at the range of 8 to 10 g/dl. Overall life expectancy 
on dialysis was 10.13 years with superior life expectancy for
haemodialysis (11.37 years) compared to CAPD (7.94 years).
The cost per quality-adjusted life years was RM43,000 for
haemodialysis and RM41,000 for CAPD. The incremental
QALYs gained for haemodialysis and CAPD patients at haemo-
globin baseline were 2.04 and 0.27, respectively. The incremen-
tal cost per QALY gained of EPO was RM66,000 and
RM137,000 for haemodialysis and CAPD patients, respectively
at the same average baseline haemoglobin level between 8 g/dl
and 10 g/dl. CONCLUSION: With the current state of utilisa-
tion of EPO therapy in the Ministry of Health of Malaysia
setting, haemodialysis is more cost effective modality compared
to CAPD.
PUK12
DECISION MODEL OF RESOURCE (TIME) SAVINGS
GENERATED BY EXTENDED DOSING OF ERYTHROPOIESIS
STIMULATING PROTEIN (ESP) FOR THE TREATMENT OF
ANEMIA IN CHRONIC KIDNEY DISEASE (CKD) PATIENTS
Barlev A1,Young S2, Bokhari A3, Roberts K4, Globe D1
1Amgen,Thousand Oaks, CA, USA, 2Mid-Atlantic Nephrology
Associates, PA, Baltimore, MD, USA, 3WNERTA / Baystate Medical
Center, Springﬁeld, MA, USA, 4Research By Design, LLC, Evergreen
Park, IL, USA
OBJECTIVE: Three quarters of patients with CKD and anemia
are not treated with ESP prior to End Stage Renal Disease. The
capacity to provide anemia treatment in nephrology practices
may be a hindrance to early initiation of treatment in these
patients. METHODS: A decision tree was developed, simulating
annual time savings associated with ESP administration when
weekly (QW) administration is transitioned to less frequent
administration. Parameter estimates were derived from a cross-
sectional observational study assessing time utilized to adminis-
ter ESP injections to CKD anemic patients. The model has two
arms, simulating treatment over a one year period; arm “A” of
the model has four transition states which represent the fre-
quency of ESP administration (QW, Q2W (every two weeks),
QM (monthly), and “QW only”). In arm “A” 100% of the
patients start on a QW regimen. The ‘QW only’ state simulates
those patients whose hemoglobin cannot be stabilized on
extended dosing and fail transition to extended dosing. Arm “B”
has only one state, QW. RESULTS: At the end of the simulated
year, estimated ESP administration time was 263 minutes per
patient per year in arm “A” (QM) vs. 467 minutes in arm “B”
(QW). The difference in time between arm “B” and “A” results
in 3.4 hours less for arm “A”. In arm “A” 79% of patients were
in the Q4W state, 9% in Q2W, and 12% in QW and QW only.
On average, it took 3–4 months to extend the patient to QM.
CONCLUSIONS: The results of the model suggest that a
nephrology clinic could save, on average, 3.4 hours per patient
during the ﬁrst year by transitioning to less frequent ESP admin-
istration. Greater savings may be realized once the transition has
been completed, possibly providing increased capacity for treat-
ment of additional patients with CKD and anemia.
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OBJECTIVE: This study examined trends in physician-
prescribing of medications for anemia management of chronic
kidney disease (CKD) in outpatient settings in the United States.
METHODS: This cross-sectional study used data from the
National Ambulatory Medical Care Survey (NAMCS) from
1996 to 2003. Patients aged ≥18 years with chronic kidney
disease treated in the US outpatient settings were included in the
study sample. Ofﬁce visits were considered related to CKD if rel-
evant ICD-9 codes were recorded and if CKD was reported as
the reason for the visit. Similarly, ofﬁce visits were considered
related to anemia if anemia relevant ICD-9 codes were recorded
and if anemia was reported as the reason for the visit or labo-
ratory testing was ordered during the visits. Anemia medications
(Erythropoietic stimulating agents or iron replacement) were
retrieved using the NAMCS drug codes, and all analyses 
were weighted to make national estimates. RESULTS: There
were approximately 92 million weighted patient visits were made
for CKD in the outpatient settings from 1996 to 2003. Nearly
two-thirds (63%) of these visits were related to female and 54%
of these visits were by patient aged more than 65 years. Nephrol-
ogists accounted for 18% of the patient visits and 48% of the
patient reported having anemia. Only 10% of visits with anemia
resulted in a prescription for anemia medication (Erythropoietic
stimulating agents & iron replacements). There were no time-
related differences observed in these prescribing patterns. CON-
CLUSIONS: The ﬁndings of this study seem to suggest that few
visits with anemia are receiving anemia medications in US out-
patient settings, since most of the visits do not result in anemia
medication prescription.
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OBJECTIVES: Secondary hyperparathyroidism (SHPT) is a
common side effect of end-stage renal disease and is associated
with increased risk of fracture and cardiovascular events.
Cinacalcet is the ﬁrst of a new class of calcimimetic drugs, which
suppress parathyroid hormone (PTH) production. The aim of
this study is to estimate the cost-utility of cinacalcet in patients
with SHPT. Although there is convincing evidence of the posi-
tive impact of cinacalcet on serum biomarkers such as PTH, the
long-term cost and clinical implications of treatment are less
clear. METHODS: A Markov model was developed in Excel to
estimate differences in quality adjusted life years (QALYs) in
people with SHPT in end stage renal disease (ESRD) treated with
cinacalcet, compared to those receiving standard treatment
alone. The model was stratiﬁed by degree of disease progression.
Estimates of the effectiveness of cinacalcet were taken from a sys-
tematic review of the literature by the authors. Where possible,
other transition probabilities, costs and utilities all came from
published sources. Costs and beneﬁts were discounted at 3.5%
annually. The perspective of the UK National Health Service was
taken throughout. Extensive one-way and probabilistic sensitiv-
